Abstract:Drug interactions are not a new phenomenon, yet some may be overlooked simply because they are not well recognised. Recent studies have highlighted an interaction between diltiazem – a commonly prescribed non-dihydropyridine calcium channel blocker used for rate control in atrial fibrillation (AF) – and direct oral anticoagulants (DOACs) which inhibit Factor Xa to, amongst other indications, reduce stroke risk in AF. As mentioned, this is not a new concept – indeed, a pharmacokinetic study 10 years ago demonstrated a 1.4-fold increase in apixaban exposure when co-prescribed diltiazem(1). Despite this, many clinicians may be unaware of the potential for such drug-drug interactions, as anticoagulation and rate control may be viewed as unrelated aspects of AF management. Since 2014, several studies have attempted to quantify the bleeding risk associated with combining these medications. Unfortunately, such comparisons are fraught with confounding variables, and not all studies have demonstrated a significant effect. In this issue of Heart Rhythm , two new studies are presented which assess this important topic(2,3). Ang et al. present the results of a meta-analysis of almost half a million patients taking DOACs with or without diltiazem(2). A trend was seen towards increased bleeding risk, but this did not reach statistical significance (HR 1.16 [95% CI 0.94-1.42]; p=0.16). Meanwhile, Wong et al. present a large, propensity matched, retrospective study assessing bleeding alongside other outcomes in those taking DOACs and diltiazem, and other drugs such as amiodarone which may have similar effects(3). Again, no significant bleeding risk was observed with diltiazem and DOACs in combination. This latter study, whilst employing rigorous statistical techniques, likely falls prey to unmeasured confounders, based on observations which do not make clinical sense. For example, an almost 4-fold increase in mortality was seen when a DOAC was initiating whilst taking diltiazem (OR 3.79); however, initiating in the reverse order (diltiazem whilst already taking a DOAC) was associated with markedly reduced mortality (OR 0.38). The only plausible explanation for this is unmeasured confounding. By way of explanation, let us consider a patient already established on diltiazem who then initiates a DOAC. Diltiazem may have been prescribed for pre-existing AF rate control, but the lack of DOAC suggests a low thromboembolic risk, or perhaps a contraindication. For them to suddenly be initiated on a DOAC suggests their stroke risk increased – this might simply represent an increase in age, but in some cases may be due to a new diagnosis of a significant cardiovascular morbidity (e.g., diabetes), or even due to thromboembolic stroke. The latter situations clearly depict a patient at higher risk of mortality, especially if anticoagulation was previously considered contraindicated. Conversely, a patient already established on a DOAC then initiated on diltiazem likely had no change in their baseline clinical condition, other than perhaps suboptimal rate control or failure of rhythm control. This situation portends a different prognosis. These are speculative examples; however, this illustrates the degree of complexity when attempting to establish a causal relationship, especially when the factor in question – drug initiation order – should not itself have any effect. Indeed, bleeding events also are a red flag for patients at 'high risk' of major clinical events(4).

Predicting drug-drug interaction with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration

Predicting Drug-Drug Interactions with Physiologically Based Pharmacokinetic/pharmacodynamic Modelling and Optimal Dosing of Apixaban and Rivaroxaban with Dronedarone Co-Administration

Predicting Drug-Drug Interaction with Physiologically Based Pharmacokinetic/Pharmacodynamic Modelling and Optimal Dosing of Oral Anti-Coagulants with Dronedarone Co-Administration

Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban

Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling

Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population

Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database)

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

Application of Physiologically Based Pharmacokinetic Modeling to the Prediction of Drug-Drug and Drug-Disease Interactions for Rivaroxaban

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults

Potential interactions between medications for rate control and direct oral anticoagulants: population-based cohort and case-crossover study

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice

Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation

Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation

Do Non-Dihydropyridine Calcium Channel Blockers Increase Bleeding Risk with Direct Oral Anticoagulants?

Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database